Your session is about to expire
← Back to Search
Dexcom real-time G6 Continuous Glucose Monitoring System (CGM) for Type 2 Diabetes
Study Summary
This trial will help researchers learn if real-time CGM data can prevent hypoglycemia in patients with type 2 diabetes and end-stage kidney disease who are treated with insulin therapy and receiving hemodialysis.
- Type 2 Diabetes
- Kidney Failure
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You are an adult with type 2 diabetes.You are currently undergoing hemodialysis treatment for at least 90 days.You are currently performing self-monitored blood glucose (at least 2 times daily).You are willing to wear a continuous glucose monitoring device (CGM).
- Group 1: Point-Of-Care Blood Glucose (Control) then Real-time Dexcom CGM Group (Control-Intervention Group)
- Group 2: Real-time Dexcom CGM, then Point-Of-Care Blood Glucose Group (Intervention-Control Group)
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is participation in this trial open to those below the age of thirty?
"To be eligible for this trial, patients must fall within the 18 to 80 age range. Alternatively, there are 251 studies targeting those under 18 and 1638 specifically designed for senior citizens aged 65 or higher."
What criteria must people meet in order to be selected for this trial?
"To be eligible for inclusion in this medical trial, patients must have type 2 diabetes and should fall within the ages of 18 to 80. This research initiative is currently recruiting a total of 45 participants."
How many people are actively participating in this clinical experiment?
"That is correct. As detailed on the clinicaltrials.gov website, this medical trial opened for enrollment on November 5th 2020 and was most recently updated February 18th 2022. 45 patients are being sought between two different sites of study."
What is the objective of this experiment?
"The primary endpoint of this study, to be monitored over a period of three months, is the distinction in mean percentage time-in-hypoglycemia (< 70 mg/dL) between intervention and control phases. Additionally, secondary endpoints include: Proportion of CGM values within %15/15 of reference glucose values <70 mg/dL; Rate of asymptomatic and nocturnal CGM-detected hypoglycemia (<70 mg/dl); and Proportion of CGM values within ±20% or ±20 mg/dL (%20/20) of reference glucose values >250 mg/dL."
Is this examination currently seeking participants?
"Per the information available on clinicaltrials.gov, this trial is actively recruiting participants at this time. It was initially made public on November 5th 2020 and last updated a few days ago, February 18th 2022."
Who else is applying?
How old are they?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger